Characterization of chimeric prostacyclin/prostaglandin D2 receptors

European Journal of Pharmacology

Volumn 386, Issue 1, 1999, Pages 89-96

  Wise, Helen ^a  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Chimeric receptor; Constitutively active receptor; IP receptor; Partial agonist; Prostacyclin

Indexed keywords

[3 [4 (4,5 DIPHENYL 2 OXAZOLYL) 5 OXAZOLYL]PHENOXY]ACETIC ACID; CICAPROST; CYCLIC AMP; ILOPROST; PROSTACYCLIN RECEPTOR; PROSTAGLANDIN RECEPTOR;

ANIMAL CELL; ARTICLE; BINDING AFFINITY; CARBOXY TERMINAL SEQUENCE; CHIMERA; CHO CELL; DRUG POTENCY; DRUG RECEPTOR BINDING; ENZYME ACTIVITY; NONHUMAN; PRIORITY JOURNAL;

ALGORITHMS; ALPROSTADIL; AMINO ACID SEQUENCE; ANIMALS; CHO CELLS; CRICETINAE; CYCLIC AMP; GTP-BINDING PROTEIN ALPHA SUBUNITS, GS; ILOPROST; INDICATORS AND REAGENTS; MICE; MOLECULAR SEQUENCE DATA; PROSTAGLANDIN D2; RADIOLIGAND ASSAY; RECEPTORS, EPOPROSTENOL; RECEPTORS, IMMUNOLOGIC; RECEPTORS, PROSTAGLANDIN; RECEPTORS, PROSTAGLANDIN E; TRANSFECTION;

EID: 0033433985     PISSN: 00142999     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0014-2999(99)00725-6     Document Type: Article

References (30)

1. Barber R., Ray K.P., Butcher R.W. Turnover of adenosine 3′,5′-monophosphate in WI-38 cultured fibroblasts. Biochemistry. 19:1980;2560-2567.
2. 4 subtype is essential for agonist-induced desensitization. Mol. Pharmacol. 51:1997;343-349.
3. Coleman R.A., Smith W.L., Narumiya S. International Union of Pharmacology classification of prostanoid receptors: properties, distribution and structure of the receptors and their subtypes. Pharmacol. Rev. 46:1994;205-229.
4. Harazono A., Sugimoto Y., Ichikawa A., Negishi M. Enhancement of adenylate cyclase stimulation by prostaglandin E receptor EP3 subtype isoforms with different efficiencies. Biochem. Biophys. Res. Commun. 201:1994;340-345.
5. Hasegawa H., Negishi M., Ichikawa A. Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity. J. Biol. Chem. 271:1996;1857-1860.
6. Iida-Klein A., Guo J., Xie L.Y., Jüppner H., Potts J.T. Jr., Kroneberg H.M., Bringhurst F.R., Abou-Samra A.B., Segre G.V. Truncation of the carboxyl-terminal region of the rat parathyroid hormone (PTH)/PTH-related peptide receptor enhances PTH stimulation of adenylyl cyclase but not phospholipase C. J. Biol. Chem. 270:1995;8458-8465.
7. Irie A., Sugimoto Y., Namba T., Asano T., Ichikawa A., Negishi M. The C-terminus of the prostaglandin-E-receptor EP3 subtype is essential for activation of GTP-binding protein. Eur. J. Biochem. 224:1994;161-166.
8. 2-adrenoceptor. Br. J. Pharmacol. 123:1998;701-711.
9. Jin J.G., Mao G.F., Ashby B. Constitutive activity of human prostaglandin E receptor EP3 isoforms. Br. J. Pharmacol. 121:1997;317-323.
10. Kobayashi T., Kiriyama M., Hirata T., Hirata M., Ushikubi F., Narumiya S. Identification of domains conferring ligand binding specificity to the prostanoid receptor. J. Biol. Chem. 272:1997;15154-15160.
11. Leff P. The two-state model of receptor activation. Trends Pharmacol. Sci. 16:1995;89-97.
12. Namba T., Sugimoto Y., Negishi M., Irie A., Ushikubi F., Kakizuka A., Ito S., Ichikawa A., Narumiya S. Alternative splicing of C-terminal tail of prostaglandin E receptor subtype EP3 determines G-protein specificity. Nature. 365:1993;166-170.
13. 3 subtype. J. Biol. Chem. 268:1993;9517-9521.
14. 3 receptor. FEBS Lett. 401:1997;185-190.
15. Nishigaki N., Negishi M., Ichikawa A. Two Gs-coupled prostaglandin E receptor subtypes, EP2 and EP4, differ in desensitization and sensitivity to the metabolic inactivation of the agonist. Mol. Pharmacol. 50:1996;1031-1037.
16. 2-adrenergic receptor. J. Biol. Chem. 263:1988;15985-15992.
17. 2-adrenergic receptor. J. Biol. Chem. 264:1989;7564-7569.
18. Parker E.M., Ross E.M. Truncation of the extended carboxyl-terminal domain increases the expression and regulatory activity of the avian β-adrenergic receptor. J. Biol. Chem. 266:1991;9987-9996.
19. Pierce K.L., Gil D.W., Woodward D.F., Regan J.W. Cloning of the human prostanoid receptors. Trends Pharmacol. Sci. 16:1995;253-256.
20. 2-adrenergic receptor. J. Biol. Chem. 268:1993;4625-4636.
21. Scheer A., Cotecchia S. Constitutively active G protein-coupled receptors: potential mechanisms of receptor activation. J. Recept. Signal Transduction Res. 17:1997;57-73.
22. Seiler S.M., Brassard C.L., Federici M.E., Romine J., Meanwell N.A. [3-[4-(4,5-diphenyl-2-oxazolyl)-5-oxazolyl]phenoxy]acetic acid (BMY-45778) is a potent prostacyclin partial agonist: effects on platelet aggregation, adenylyl cyclase, cAMP levels, protein kinase, and iloprost binding. Prostaglandins. 53:1997;21-35.
23. 2 -adrenoceptor and type II adenylyl cyclase. Br. J. Pharmacol. 123:1998;335-343.
24. 3 receptor with different carboxyl-terminal domains. J. Biol. Chem. 268:1993;2712-2718.
25. Ushikubi F., Hirata M., Narumiya S. Molecular biology of prostanoid receptors; an overview. J. Lipid Mediators Cell Signalling. 12:1995;343-359.
26. Whaley B.S., Yuan N., Birnbaumer L., Clark R., Barber R. Differential expression of the β-adrenergic receptor modifies agonist stimulation of adenylyl cyclase: a quantitative evaluation. Mol. Pharmacol. 45:1994;481-489.
27. Wise H. The inhibitory effects of non-prostanoid prostacyclin mimetics on rat neutrophil function. Prostaglandins Leukot. Essent. Fatty Acids. 54:1996;351-360.
28. Wise H., Chow B.S. Effect of non-prostanoid prostacyclin mimetics on cyclic AMP production by neuronal SK-N-SH cells. Prostaglandins Leukot. Essent. Fatty Acids. 55(Suppl. 1):1996;35.
29. Wise, H., Kobayashi, T., Hong, L.L., Chow, K.B.S., 1998. Modification of the carboxyl-terminal tail of the prostacyclin (IP)-receptor increases the efficacy of the IP-receptor partial agonist, BMY 45778. Proc. 1st IUPHAR Conference p28.
30. Yuan N., Friedman J., Whaley B.S., Clark R.B. cAMP-dependent protein kinase and protein kinase C consensus site mutations of the β-adrenergic receptor. J. Biol. Chem. 269:1994;23032-23038.